BioCentury
ARTICLE | Company News

Cell Therapeutics sales and marketing update

September 17, 2012 7:00 AM UTC

Cell Therapeutics launched Pixuvri pixantrone in Sweden, Denmark and Finland to treat patients with multiply relapsed or refractory aggressive non-Hodgkin's B cell lymphoma. The company said launches in Austria and Norway are expected next month, with launches in Germany, the U.K. and the Netherlands planned for November. The aza-anthracenedione DNA intercalating agent that inhibits topoisomerase II (TOP2) is slated for launch in France, Italy and Spain next year.

The European Commission granted conditional approval for Pixuvri for the indication in May. Cell Therapeutics said the product, which was previously available in the EU through a named-patient program, is the first therapy to be approved for the indication in the EU. In June, the company announced it would restructure to align resources and prioritize its pipeline in part to focus on the EU launch of Pixuvri (see BioCentury, May 14 & June 25). ...